Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Non-Current Liabilities (2016 - 2026)

Ani Pharmaceuticals' Other Non-Current Liabilities history spans 12 years, with the latest figure at $9.6 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities fell 11.83% to $9.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.6 million, a 11.83% decrease, with the full-year FY2025 number at $9.6 million, down 11.83% from a year prior.
  • Other Non-Current Liabilities hit $9.6 million in Q4 2025 for Ani Pharmaceuticals, down from $11.3 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for ANIP hit a ceiling of $32.1 million in Q1 2022 and a floor of $1.0 million in Q2 2022.
  • Historically, Other Non-Current Liabilities has averaged $8.9 million across 5 years, with a median of $8.8 million in 2021.
  • The widest YoY moves for Other Non-Current Liabilities: up 1089.81% in 2023, down 96.25% in 2023.
  • Tracing ANIP's Other Non-Current Liabilities over 5 years: stood at $7.8 million in 2021, then tumbled by 82.3% to $1.4 million in 2022, then skyrocketed by 248.23% to $4.8 million in 2023, then surged by 126.66% to $10.9 million in 2024, then dropped by 11.83% to $9.6 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for ANIP at $9.6 million in Q4 2025, $11.3 million in Q3 2025, and $6.7 million in Q2 2025.